Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Somatostatin receptor PET response assessment framework for patients with neuroendocrine tumours (V1.0): a modified Delphi consensus from the European Neuroendocrine Tumor Society (endorsed by EANM and NANETS).

The Lancet. Oncology·2026
Same authorSame journal

Systemic radionuclide treatments in gastro-entero-pancreatic neuroendocrine tumours.

Current opinion in oncology·2026
Same author

Quantitative accuracy of <sup>177</sup>Lu SPECT/CT imaging using ring-shaped CZT versus dual-head NaI systems.

EJNMMI physics·2026
Same author

Toward Personalized Radiopharmaceutical Therapy: Radiobiologic Insights Compared with External-Beam Radiotherapy.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

<sup>211</sup>At targeted alpha therapy in Europe: overcoming clinical, regulatory, and infrastructure challenges.

European journal of nuclear medicine and molecular imaging·2026
Same author

Preoperative Assessment of Peritoneal Carcinomatosis with [<sup>68</sup>Ga]Ga-FAPI-46 PET/CT: Agreement with Surgicopathologic PCI and Comparison with MRI and [<sup>18</sup>F]FDG PET/CT.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026

Related Experiment Video

Updated: Oct 31, 2025

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.3K

Targeted radionuclide therapy: an emerging field in solid tumours.

Carlos Artigas1, Magdalena Mileva, Patrick Flamen

  • 1Department of Nuclear Medicine, Institut Jules Bordet, Université Libre de Bruxelles (ULB), Brussels, Belgium.

Current Opinion in Oncology
|June 29, 2021
PubMed
Summary

Targeted radionuclide therapy (TRNT) offers a theranostic approach for solid tumors. This method uses radiolabeled drugs for precise tumor targeting, improving patient outcomes in neuroendocrine and prostate cancers.

More Related Videos

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.6K
PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator
10:48

PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator

Published on: December 28, 2017

9.7K

Related Experiment Videos

Last Updated: Oct 31, 2025

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.3K
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.6K
PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator
10:48

PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator

Published on: December 28, 2017

9.7K

Area of Science:

  • Nuclear medicine
  • Oncology
  • Radiopharmaceutical therapy

Background:

  • Targeted radionuclide therapy (TRNT) involves administering radiolabeled drugs to target specific molecular alterations on tumor cells.
  • Small molecules labeled with beta or alpha-emitting radioisotopes deliver radiation directly to tumor sites.
  • Theranostics combine therapeutic administration with pretreatment imaging using similar radiolabeled drugs.

Purpose of the Study:

  • To review current clinical research findings and applications of TRNT in solid tumors.
  • To focus on the use of TRNT in neuroendocrine and prostate neoplasms.
  • To highlight the theranostic potential of radionuclide applications in nuclear medicine.

Main Methods:

  • Systemic administration of radiolabeled drugs.
  • Targeting specific molecular alterations on tumor cells.
  • Pretreatment imaging for biodistribution assessment.

Main Results:

  • Peptide receptor radionuclide therapy is key in managing neuroendocrine tumors, improving quality of life and survival.
  • 177Lu-PSMA radioligand therapy shows high response rates in metastatic castration-resistant prostate cancer.
  • Emerging targets like fibroblast activation proteins show promising theranostic results.

Conclusions:

  • TRNT is established for neuroendocrine tumors and prostate cancer.
  • New molecular targets will expand theranostic applications.
  • TRNT enhances precision medicine in oncology.